Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’

Correspondence to Dr Enrique Calvo-Aranda, Rheumatology, Hospital Universitario Infanta Leonor, Madrid, Spain; e-mail: [email protected]

Received November 13, 2020; Accepted November 17, 2020

Twitter@enriquecalvoA, @IrenCanamares, @lvaroMartnezAlc, @EscobarIsmael3

Contributors EC-A: Conceptualisation, methodology, formal analysis, investigation, resources, writing—original draft, review and editing, supervision, project administration. IC-O: data curation, writing—original draft, review and editing. MNN: methodology, formal analysis, investigation, data curation, writing—review and editing. AM-A: conceptualisation, methodology, formal analysis, software, writing—review and editing, investigation, resources, supervision, project administration. MdCOdlO: investigation, resources, writing—review and editing. IE-R: conceptualisation, methodology, formal analysis, investigation, writing—original draft, review and editing, FMS: investigation, resources, writing—review and editing.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests C-A reports personal fees from SOBI, personal fees (less than 10.000$ each) from NOVARTIS, personal fees from GEBRO PHARMA, personal fees from PFIZER, personal fees from ABBVIE, personal fees from LILLY, personal fees from GRUNENTHAL, personal fees from SANOFI, outside the submitted work.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Provenance and peer review Not commissioned; internally peer reviewed.